

INSTITUTIONAL ETHICS COMMITTEE

Date: 29.09.2020

The request for giving information of study in website is discussed in the Institutional ethics committee. The following information is approved to be published in the web site.

Study details


1. Protocol Title: APD334-301 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
2. Protocol Title: APD334-302 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
3. Protocol Title: APD334-303 An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis

Text content:

"Ulcerative Colitis: Aster Medcity, Aster Centre for Clinical Research is a participating centre for a Government Drug Controller General of India (DCGI Regulatory Authority for Clinical Trials in India) approved Phase III trial in patients with moderately to severe active Ulcerative Colitis(U.C). After the initial screening, patients who are eligible to participate in the study will be treated with an oral Investigational Product Vs Placebo drug.

For more details about the study please visit <http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=38533&EnchId=&userName=CTRI/2020/01/022642>. You can also contact 949580559 0/9611570414 at Aster Medcity for booking an appointment."




Dr. Vijayamohan S - Member Secretary
Institutional Research and Ethics Committee
Aster Medcity, Kochi.